Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 3/20 | 0.74 |
| ▸ | CSF1R | P07333 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.64 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.64 |
| ▸ | LCK | P06239 | 1/20 | 0.64 |
| ▸ | PIM1 | P11309 | 1/20 | 0.64 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.64 |
| ▸ | CDK2 | P24941 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 1/20 | 0.64 |
| ▸ | FRK | P42685 | 1/20 | 0.64 |
| ▸ | CLK2 | P49760 | 1/20 | 0.64 |
| ▸ | GSK3A | P49840 | 1/20 | 0.64 |
| ▸ | GSK3B | P49841 | 1/20 | 0.64 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.64 |
| ▸ | STK3 | Q13188 | 1/20 | 0.64 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30043560 | 1.00 | MAP2 (0.74) | MAP2CSF1RKDM4EATMROCK2 | |
| SCHEMBL4847744 | 0.89 | MAP2 (0.72) | MAP2CSF1RKDM4EATMROCK2 | |
| SCHEMBL19863777 | 0.88 | CSF1R (0.60) | MAP2CSF1RKDM4EATMROCK2 | |
| SCHEMBL4854377 | 0.88 | CSF1R (0.69) | MAP2CSF1RKDM4EATMROCK2 | |
| Hydrochloric Acid SCHEMBL4854389 | 0.88 | MAP2 (0.71) | MAP2CSF1RKDM4EATMROCK2 | |
| SCHEMBL16814471 | 0.88 | MAP2 (0.60) | MAP2CSF1RKDM4EATMROCK2 | |
| SCHEMBL19857781 | 0.87 | IKBKB (0.57) | MAP2CSF1RKDM4EATMROCK2 | |
| SCHEMBL17457314 | 0.87 | CSF1R (0.57) | MAP2CSF1RKDM4EATMROCK2 | |
| SCHEMBL14916827 | 0.86 | CSF1R (0.77) | MAP2CSF1RKDM4EATMROCK2 | |
| SCHEMBL17457309 | 0.86 | PADI4 (0.66) | MAP2CSF1RATMPADI4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052747-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | TES PHARMA S.R.L. (IT) | 2023-02-16 | — | — | US | disclosed |
| US-20230052747-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | TES PHARMA S.R.L. (IT) | 2023-02-16 | — | — | US | disclosed |
| WO-2021116999-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021116999-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2021-06-17 | — | — | WO | disclosed |
| EP-2968360-B1 | QUINOLINONE DERIVATIVES FOR THE INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2021-01-20 | — | — | EP | disclosed |
| US-10717739-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2020-07-21 | — | — | US | disclosed |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190345162-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | CONVERGENE LLC | 2019-11-14 | — | — | US | disclosed |
| US-10266536-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180044324-A1 | Quinolinones as Inhibitors of Translation Initiation Complex | Sanford Burnham Prebys Medical Discovery Institute | 2018-02-15 | — | — | US | disclosed |
| US-9695179-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | CONVERGENE LLC (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2968360-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | ConverGene LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014159837-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | CONVERGENE LLC (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20100168162-A1 | SELECTIVE INHIBITORS OF AKT AND METHODS OF USING SAME | THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-07-01 | — | — | US | disclosed |
| EP-1404329-A4 | SUBSTITUTED 4-ARYL-3-(3-ARYL-1-OXO-2-PROPENYL)-2(1H)-QUINOLINONES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20050165053-A1 | Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-07-28 | — | — | US | disclosed |
| EP-1404329-A1 | SUBSTITUTED 4-ARYL-3-(3-ARYL-1-OXO-2-PROPENYL)-2(1H)-QUINOLINONES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| WO-2002098425-A1 | SUBSTITUTED 4-ARYL-3-(3-ARYL-1-OXO-2-PROPENYL)-2(1H)-QUINOLINONES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717739-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | BRPF3, BRD3, BRDT | MAP2 323/4885CSF1R 3174/4885KDM4E 1194/4885 |
| US-20230052747-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | RAD51, BRCA1, FANCI | MAP2 2597/4885CSF1R 4611/4885KDM4E 4394/4885 |
| US-20190345162-A1 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | BRPF3, BRD3, BRDT | MAP2 323/4885CSF1R 3174/4885KDM4E 1194/4885 |
| US-10266536-B2 | Methods and compositions for inhibition of bromodomain-containing proteins | BRPF3, BRD3, BRDT | MAP2 323/4885CSF1R 3174/4885KDM4E 1194/4885 |
| US-20180044324-A1 | Quinolinones as Inhibitors of Translation Initiation Complex | EIF4E, EIF4A1, EIF4A2 | MAP2 998/4885CSF1R 4194/4885KDM4E 1264/4885 |
| US-10577349-B2 | Quinolinones as inhibitors of translation initiation complex | EIF4E, EIF4A1, EIF4A2 | MAP2 998/4885CSF1R 4194/4885KDM4E 1264/4885 |
| US-20160024096-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, BRD3, BRDT | MAP2 323/4885CSF1R 3174/4885KDM4E 1194/4885 |
| US-20050165053-A1 | Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP3, CASP2 | MAP2 1534/4885CSF1R 2134/4885KDM4E 1757/4885 |
| US-20100168162-A1 | SELECTIVE INHIBITORS OF AKT AND METHODS OF USING SAME | AKT1S1, AKT1, PIK3CA | MAP2 1776/4885CSF1R 3140/4885KDM4E 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.